Cleared Traditional

K990822 - RAPIDONE - COCAINE TEST

K990822 is an FDA 510(k) clearance for RAPIDONE - COCAINE TEST, manufactured by American Bio Medica Corp.. The device is a Class 2 Toxicology device with product code DIO cleared through the Traditional 510(k) pathway after a 126-day FDA review.

K990822 · American Bio Medica Corp. · Toxicology device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Jul 1999
Decision
126d
Days
Class 2
Risk

K990822 is an FDA 510(k) clearance for the RAPIDONE - COCAINE TEST. Classified as Enzyme Immunoassay, Cocaine And Cocaine Metabolites (product code DIO), Class II - Special Controls.

Submitted by American Bio Medica Corp. (Washington, US). The FDA issued a Cleared decision on July 15, 1999 after a review of 126 days - within the typical 510(k) review window.

This device falls under the Toxicology FDA review panel, regulated under 21 CFR 862.3250 - the FDA toxicology device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Standard predicate-based submission. Standard predicate reliance. This clearance follows a standard predicate-based equivalence path within the Toxicology review framework, consistent with the majority of Class II 510(k) submissions.

View all American Bio Medica Corp. devices

FDA 510(k) Submission Details - K990822

510(k) Number K990822 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received March 11, 1999
Decision Date July 15, 1999
Days to Decision 126 days
Submission Type Traditional
Review Panel Toxicology (TX)
Summary Summary PDF
Third-party Review No - reviewed directly by FDA
Combination Product No
PCCP Authorized No
Regulatory Context
Review time vs. panel average
39d slower than avg
Panel avg: 87d · This submission: 126d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

DIO Device Classification - Class 2, Special Controls

Product Code DIO Enzyme Immunoassay, Cocaine And Cocaine Metabolites
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 862.3250
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Toxicology devices follow this clearance model.

Regulatory Peers - DIO Enzyme Immunoassay, Cocaine And Cocaine Metabolites

All 104
Devices cleared under the same product code (DIO) and FDA review panel - the closest regulatory comparables to K990822.
QUICKPAC II ONE STEP COCAINE TEST
K992990 · Syntron Bioresearch, Inc. · Sep 1999
DRUGCHECK X MULTIDRUG SCREENING DEVICE
K992748 · Syntron Bioresearch, Inc. · Sep 1999
QUIKSTRIP ONE STEP COCAINE ASSAY (COCAINE AND COCAINE METABOLITE TEST SYSTEM
K992207 · Syntron Bioresearch, Inc. · Jul 1999
MODIFICATION TO ABUSCREEN ONLINE COCAINE METABOLITE
K983697 · Roche Diagnostic Systems, Inc. · Dec 1998
AUTO-LYTE COCAINE METABOLITE EIA, MODEL # 1222U
K982759 · OraSure Technologies, Inc. · Nov 1998
DBEST COCAINE TEST KIT
K983191 · Ameritek, Inc. · Nov 1998